In a comprehensive assessment of the RV-1730 vaccine’s efficacy and dose-response, we utilized a mouse model of lethal infection by immunizing human ACE2 knocked-in K18-hACE2 mice with RV-1730. This evidence concerns the gene ACE2 and infection.